Pulmonx Corp Ownership
| LUNG Stock | USD 6.61 0.18 2.65% |
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 39 M | Current Value 39 M | Avarage Shares Outstanding 28.9 M | Quarterly Volatility 15 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Pulmonx |
Pulmonx Stock Ownership Analysis
About 95.0% of the company shares are owned by institutional investors. The book value of Pulmonx Corp was now reported as 2.38. The company recorded a loss per share of 1.47. Pulmonx Corp had not issued any dividends in recent years. Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. Pulmonx Corp operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 253 people. To find out more about Pulmonx Corp contact Steven Williamson at 650 364 0400 or learn more at https://pulmonx.com.Besides selling stocks to institutional investors, Pulmonx Corp also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pulmonx Corp's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pulmonx Corp's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pulmonx Corp Quarterly Liabilities And Stockholders Equity |
|
Pulmonx Corp Insider Trades History
About 5.0% of Pulmonx Corp are currently held by insiders. Unlike Pulmonx Corp's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Pulmonx Corp's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Pulmonx Corp's insider trades
Pulmonx Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pulmonx Corp is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pulmonx Corp backward and forwards among themselves. Pulmonx Corp's institutional investor refers to the entity that pools money to purchase Pulmonx Corp's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Franklin Resources Inc | 2024-09-30 | 700.4 K | Rock Springs Capital Management Lp | 2024-06-30 | 652.4 K | Pura Vida Investments, Llc | 2024-09-30 | 509.8 K | Altium Capital Management, Lp | 2024-09-30 | 500 K | Millennium Management Llc | 2024-06-30 | 448.6 K | Partner Fund Management Lp | 2024-09-30 | 368.9 K | Northern Trust Corp | 2024-09-30 | 362.2 K | D. E. Shaw & Co Lp | 2024-09-30 | 360.8 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 347.5 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 6.9 M | Fmr Inc | 2024-09-30 | 5.9 M |
Pulmonx Corp Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulmonx Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulmonx Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pulmonx Corp insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pulmonx Corp Outstanding Bonds
Pulmonx Corp issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pulmonx Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pulmonx bonds can be classified according to their maturity, which is the date when Pulmonx Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| PulteGroup 6 percent Corp BondUS745867AT82 | View | |
| PulteGroup 55 percent Corp BondUS745867AW12 | View | |
| PulteGroup 5 percent Corp BondUS745867AX94 | View | |
| PulteGroup 7875 percent Corp BondUS745867AM30 | View | |
| PulteGroup 6375 percent Corp BondUS745867AP60 | View |
Pulmonx Corp Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 1st of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 30th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 21st of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Pulmonx Corp is a strong investment it is important to analyze Pulmonx Corp's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmonx Corp's future performance. For an informed investment choice regarding Pulmonx Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pulmonx Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Pulmonx Stock please use our How to Invest in Pulmonx Corp guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmonx Corp. If investors know Pulmonx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmonx Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.47) | Revenue Per Share 2.043 | Quarterly Revenue Growth 0.154 | Return On Assets (0.20) | Return On Equity (0.52) |
The market value of Pulmonx Corp is measured differently than its book value, which is the value of Pulmonx that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmonx Corp's value that differs from its market value or its book value, called intrinsic value, which is Pulmonx Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmonx Corp's market value can be influenced by many factors that don't directly affect Pulmonx Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulmonx Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmonx Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmonx Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.